ArticleInternational braz j urol : official journal of the Brazilian Society of Urology
Validation of the Brazilian Version of the Cambridge Renal Stone Patient-Reported Out-come Measure (Br-CReSP) versus a Generic Questionnaire for Assessing Health-Related Quality of Life in Nephrolithiasis.
Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNo validated tool specifically assesses health-related quality of life (HRQoL) in Brazilian patients with kidney stones. The Cambridge Renal Stone Patient-Reported Outcome Measure (CReSP) is a self-administered questionnaire that evaluates the impact of kidney stones on patients' QoL over the preceding seven days. This study aimed to translate the CReSP into Portuguese, validate it, and compare it with the validated generic SF-12 questionnaire. MATERIALS AND
methodsThe CReSP questionnaire was translated into Portuguese following Guillemin's guidelines. Patients with and without kidney stones completed the Brazilian version of the CReSP (Br-CReSP) and SF-12 questionnaires. Internal consistency, test-retest reliability, discriminant validity, and convergent validity with SF-12 components were evaluated. Logistic regression assessed the discriminant capacity of Br-CReSP and SF-12 components for nephrolithiasis.
resultsOne hundred patients completed both questionnaires. Internal consistency was high across all domains and the total score (Cronbach's α = 0.92). Test-retest reliability demonstrated strong correlations for all domains and the total score (ICC = 0.94). Discriminant validity was evidenced by significant differences between patients with and without kidney stones, with large effect sizes. Convergent validity was shown by significant inverse correlations between the Br-CReSP and SF-12 (p < 0.001). The Br-CReSP outperformed PCS-12 and MCS-12 in predicting nephrolithiasis (AUC = 0.91 vs. 0.84 and 0.73, respectively).
conclusionsThe validated Br-CReSP outperforms SF-12 in assessing HRQoL in Brazilian patients with kidney stones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.